top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


Integrating Teams After M&A or Strategic Partnerships
Value is driven by what happens bringing together individuals and teams In life sciences, mergers, carve‑outs and strategic alliances are now core to how pipelines advance and products reach patients. But while the deal thesis is usually about science, assets and markets, value is delivered (or destroyed) by what happens with people and ways of working in the first 12–18 months. This year has seen so many significant acquisition, across biotech and medtech, a few of the most
sharonshieldsconsu
Nov 126 min read


Q3 Pharma Earnings: Portfolio Renewal, Therapeutic-Area Concentration, and the Shift to Innovation-Led Growth
Q3 pharmaceutical results highlight a sector moving beyond pandemic-driven revenues toward innovation-led growth. Demand for obesity and specialty medicines is driving strong performance for companies with differentiated products, while mature and COVID-related portfolios continue to face pressure. Acquisitions and portfolio renewal are reshaping growth prospects, even as one-off costs can obscure underlying performance.
For life sciences leaders, this shift has implications
sharonshieldsconsu
Nov 95 min read


Remember, Remember the Fifth of November: Biotech’s Fireworks, Sparks and Slow Burns
Remember, remember the fifth of November—the night when bonfires burn, fireworks light the sky and everyone looks up to see what will explode next. Biotech has its own Fireworks Night. This year’s display featured headline-grabbing rockets: GLP‑1 deals, gene editing milestones, renewed enthusiasm for RNA and a more disciplined wave of AI‑in‑drug‑discovery stories. But, as every investor knows, not everything that launches reaches the same height.
For biotech insiders and inv
sharonshieldsconsu
Nov 53 min read


Autumn Inflection Point: Approvals, AI, & Capital Put Life Sciences in Overdrive
Autumn inflection point: approvals, AI, and capital are putting life sciences into overdrive. As summer turns to fall, the sector is accelerating, not slowing—driven by a cluster of FDA approvals in high‑unmet‑need diseases, breakthrough gene therapies, new guidance for AI‑enabled and microbiome-based technologies, and rising deal and funding activity. For biopharma leaders and investors, this late‑summer surge signals a pivotal moment to engage, partner, and deploy capital a
sharonshieldsconsu
Aug 296 min read
bottom of page